QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient

Pierangelo Chinello‡, Nicola Petrosillo‡, Silvia Pittalis‡, Gianluigi Biava‡, Giuseppe Ippolito‡, Emanuele Nicastri‡*, on behalf of the INMI Ebola Team¶

Lazzaro Spallanzani National Institute for Infectious Diseases (INMI), IRCCS, Rome, Italy

‡ Authors SP, GB, and GI contributed equally to preparing the case discussion and reviewed the manuscript. Authors PC, NP, and EN contributed equally to preparing the case report.
¶ Membership of the INMI Ebola Team is provided in the Acknowledgments.
* emanuele.nicastri@inmi.it

Introduction

Life-threatening arrhythmias, including torsades de pointes and ventricular fibrillation, may be induced by corrected QT (QTc) interval prolongation. Several antimicrobial drugs have been associated with QTc interval prolongation [1,2]. Favipiravir is an inhibitor of the RNA-dependent RNA polymerase of many RNA viruses, including influenza viruses, arenaviruses, phleboviruses, hantaviruses, flaviviruses, enteroviruses, and noroviruses [3]. Favipiravir has also been used in the recent epidemic of Ebolavirus (EBOV) in West Africa [4]. To date, no significant effects of favipiravir on the QT/QTc interval have been detected [5]. We report a case of QTc interval prolongation during favipiravir therapy in an EBOV-infected patient treated at our institution.

Presentation of case

A 37-year-old Italian male nurse worked in Sierra Leone from February 15, 2015, to May 7, 2015, during the West Africa EBOV epidemic and subsequently returned home to Sardinia (Italy). A few days after his return, on May 10, 2015, he started complaining of fever, chills, and arthromyalgia. On May 11, he was admitted to the Sassari Hospital isolation unit, and his blood samples were sent to the Virologic Laboratory of the Lazzaro Spallanzani National Institute for Infectious Diseases (INMI) in Rome, where the diagnosis of EBOV infection was made. On May 13, he was medically evacuated to the Lazzaro Spallanzani institute in high-isolation condition. On admission, his blood tests showed a leucocyte count of 4,000 cells/mmc (neutrophils 67%, lymphocytes 27%), haemoglobin 17.2 g/dL, platelets 79,000/mmc, glucose 77 mg/dL, creatinine 0.92 mg/dL, K\(^+\) 3.5 mEq/L, Na\(^+\) 147 mEq/L, aspartate aminotransferase 181 U/L, alanine aminotransferase 43 U/L, total bilirubin <0.5 mg/dL, and creatine phosphokinase 785 U/L; EBOV viraemia was 5 x 10\(^7\) cp/mL. He was febrile, prostrated, with mild dyspnea (oxygen saturation level [SatO\(_2\)] 88% in room air), slow ideation, and diarrhoea. On May 15, a 12-lead ECG was recorded (Fig 1): the QT interval was 320 msec, the frequency rate was 84 bpm, and the QTc was 378 msec, as calculated by Bazett formula [6]. The patient was treated with oral favipiravir (Toyama Chemical Co., Ltd., Japan) from May 13 to May 22 (6 g on the first day and 1.2 g twice daily on the following days), mefloquine 250 mg 1 tablet/week (on May 8, 15, 23, and 30), furosemide 25 mg twice daily from May 14 to June 5, omeprazole 20 mg twice daily from May 14 to June 10, levofloxacin 750 mg daily from May 13 to 19, ceftriaxone 2 g daily from May 13 to 20, and intravenous rehydration; he also received two doses of investigational monoclonal antibodies against EBOV (MIL77; Mabworks, Beijing, China) on
May 13 and 16. On May 22, the last day of favipiravir therapy, a QT interval of 480 msec, a pulse rate of 59 bpm, and a calculated QTc of 476 msec were recorded (Fig 2). On that day, plasma $K^+$ was 3.95 mEq/L, $Na^+$ 134 mEq/L, $Ca^{++}$ 1.08 mmol/L, and creatine phosphokinase 31 U/L; no other cardiac biomarkers have been collected. After favipiravir withdrawal, the QTc interval decreased to 405, 413, and 383 msec on May 25, May 28, and June 5, respectively. Plasma EBOV viraemia was negative from May 21 (Fig 3). After an initial improvement of clinical conditions with disappearance of fever, diarrhoea, and dyspnea, the clinical course was complicated by a new onset of fever on May 24 associated with lymphadenopathy, petechial skin rash, and low platelet count. Pericardial effusion was detected by echocardiography on
May 25; no further evidence of pericarditis, myopericarditis, and/or ischemia has been found. No signs of new infections were detected, and in the suspicion of an immunologic overreaction to EBOV infection, the patient was given steroid treatment starting May 26 with progressive normalisation of the clinical picture. He was discharged from the hospital in good general conditions and with a QTc interval within normal limits on June 10, 2015.

Case discussion

Favipiravir is a pyrazinecarboxamide derivative released in 2002 in Japan as an inhibitor of influenza virus replication [7]. It subsequently proved activity against several classes of viruses, including EBOV [8], and was used in both therapy and postexposure prophylaxis during the recent EBOV epidemic in West Africa [9]. In their recent work, Kumagai and colleagues [5] found no effect of favipiravir on the QT interval in healthy Japanese adults after administration of single oral doses of favipiravir 1,200 and 2,400 mg. To the best of our knowledge, there are no other studies assessing this issue [4,10]. Our patient was treated with favipiravir doses much higher than those reported by Kumagai and colleagues, i.e., 6 g on day 1 and 2.4 g on the following days, and this could explain a previously unreported effect on QTc interval prolongation. Other drugs administered to the patient, namely levofloxacin and mefloquine, had the potential to prolong the QTc interval. Levofloxacin was withdrawn three days before the registration of the longest QTc interval, and it is known to have an elimination half-life of 6.0 hours to 8.9 hours after oral and intravenous doses in patients with normal renal function [11]; however, tissue accumulation of levofloxacin could have had a role in increasing the patient’s susceptibility to drugs with QTc-prolonging potential. On the other hand, mefloquine exhibits a considerably high cardiac safety index [12], and its administration as antimalarial prophylaxis continued until May 30, 2015, when QTc interval was already shortened after favipiravir withdrawal, thus suggesting that it had a minor role in this patient’s QTc interval prolongation. A prolonged use of proton pump inhibitors (PPIs) has been associated with hypomagnesaemia and subsequent QT interval prolongation [13]. We could not dose Mg plasma levels in our patient, but the short use of PPI and the reduction of QTc interval while continuing PPI therapy make the role of omeprazole unlikely in prolonging the QTc interval. Other electrolyte disturbances, particularly hypokalaemia, may induce QTc interval prolongation. Our patient, however, had K⁺, Na⁺, and Ca²⁺ within the normal range when the longest QTc interval was recorded.

QTc prolongation has already been described in other EBOV-infected patients treated outside Africa [14,15]. In the first case, it was attributed to metabolic acidosis in the context of
severe sepsis [14]. Chertow et al. attributed the QTc elongation to concomitant administration of propofol, but their patient presented with myocarditis—confirmed by imaging—that could have also contributed to the QTc prolongation [15]. Evidence of pericarditis has also been described at autopsy in a macaque who experienced a delayed death with a decline in clinical condition after first apparent clinical recovery [16], and presence of EBOV antigen is well described within cardiac tissue and pericardial bag [17].

Whether the development of a cardiac effusion and its etiology could have impacted the QTc in our patient remains unclear. The prolonged QTc is detected only 3 days before the cardiac effusion has been noted. Unfortunately, we did not perform any cardiac imaging on May 22, 2015, when the QTc interval prolongation was noted. Pericardial effusion may have been already present at that time, and we cannot exclude that correction of the QTc could have been influenced also by the steroid therapy that resolved the effusion and the immunologic reaction. However, the ECGs performed on May 23, May 24, and May 25, (before the beginning of steroid therapy) showed a QTc of 453, 476, and 405 msec, respectively: the normalisation of the QTc interval before the beginning of steroid therapy, together with the short plasma half-life of favipiravir [18], suggests a more likely role of favipiravir withdrawal in QTc interval normalisation.

Encephalitis or central nervous system (CNS) pathology may have a role in prolonging QTc interval. However, the patient’s slow ideation noted on admission improved quickly, and no signs of encephalitis or CNS pathology were present when the QTc interval prolongation was recorded.

In conclusion, we suggest that favipiravir administered at high doses, together with the cofactors discussed above, may have contributed to inducing a QTc interval prolongation in our EBOV patient. Early extinguishing of levofloxacin and removal of the favipiravir were sufficient for correction over time.

The QTc interval reached 476 msec on the last day of favipiravir therapy; the side effect was therefore mild and should be weighed against the benefits expected in the treatment of one of the most dreadful infections in the world. If feasible, ECG monitoring could be advisable during high-dose favipiravir therapy, especially when patients experience electrolyte disturbances and concomitant use of drugs with QTc-prolonging potential.

Ethics statement

The patient gave consent to have his case details published. The authors’ institutional ethics committee approved this study.

Key learning points

- In the treatment of EBOV infection, favipiravir is used at higher doses than in the treatment of influenza.
- High doses of favipiravir could cause side effects unrecognised at common doses.
- Electrolyte disturbances are common during EBOV infection and may induce QTc interval prolongation.
- ECG monitoring could be advisable during high-dose favipiravir therapy, especially when patients experience electrolyte disturbances and concomitant use of drugs with QTc-prolonging potential.
Acknowledgments

We gratefully acknowledge the generous assistance and valuable information provided to us by Nahoko Shindo (World Health Organization [WHO], Geneva Switzerland) and Gary Kobinger (Laval University, Canada), Lionel de Moisy and Frédéric Grelet (EPRUS French Establishment for the Preparation and Response to Health Emergencies), Michael Jacobs (the Queen’s Royal Free Hospital, London, England), Hiroshi Kitaguchi and Satoru Uriya (Toyama Chemical Co., Ltd., Japan and Fuji Chemical Industry Co., Ltd., Japan, respectively), and Alessandro Agresta (Lazzaro Spallanzani INMI, Epidemiology Unit, Rome, Italy). Favipiravir was kindly provided by Toyama Chemical Co., Ltd.

Members of the INMI Ebola Team are listed below.

ID specialists: Nicola Petrosillo, Emanuele Nicastri, Nazario Nicolaci, Pierangelo Chinnenlo, Stefania Cicalini, Angela Corpolongo, Vincenzo Galati, Andrea Mariano, Silvia Rosati, Fabrizio Taglietti, Laura Vincenzi; Intensive care physicians: Mario Antonini, Ilaria Caravella, Gabriele Garotto, Luisa Marchioni, Micaela Marrit, Pyschologist: Pietro Balestra and Martina Ricottini; Radiologist: Elisa Busi Rizzi; Cardiologist: Gianluigi Biava; Virology and microbiology laboratory personnel: Maria Rosaria Capobianchi, Antonino di Caro, Concetta Castilletti, Licia Bordi, Eleonora Lalle, Mirella Biava, Silvia Meschi, Daniele Lapa, Patrizia Marsella, Francesca Colavita, Roberta Chiappini, Antonio Mazzarelli, Serena Quartu, Chiara Agrati, Fabrizio Carletti, Federica Forbici, Maria Beatrice Valli, Isabella Abbate, Alessandra Amendola, Anna Rosa Garbuglia, Maria Grazia Paglia, Eugenio Bordi, Damiano Travaglini, Antonietta Toffoletti; Nurses: Gianni Battisti, Alessanda Coppola, Loredana De Marchis, Nicola De Marco, Paolo Giacomini, Fabio Di Gianbattista, Mario Guiducci, Antonio Marasco, Antonella Marzolini, Alessandro Mercuri, Paola Nieddu, Silvia Onededei, Maurizio Vescovo, Laura Vitolo; Radiology technician: Maurizio Morea; Biocontainment ambulance drivers: Gaetano Battisti, Marco Liguori.

Members of the INMI crisis unit: Nicola Petrosillo, Emanuele Nicastri, Francesco Nicola Lauria, Vincenzo Puro, Mario Antonini, Antonio Russo, Maria Rosaria Capobianchi, Antonio Di Caro, Paolo D’Aprile, Antonella Petrecchia, Evangeliou Boumis, Marco Gentile, Damiano Travaglini, Silvia Pittalis, Lorenza Martini, Concetta Castilletti, Francesco Maria Fusco, Simone Lanini, Andrea Antinori, Marina Cerimele, Giuseppe Ippolito, and Marta Branca.

References

1. Owens RC, Nolin TD. Antimicrobial-associated QT interval prolongation: points of interest. Clin Infect Dis 2006; 43:1603–11. https://doi.org/10.1086/508873 PMID: 17109296
2. Chinello P, Petrosillo N. QT interval prolongation and antiretroviral treatment: another point of interest. Clin Infect Dis 2007; 44:1388–9. https://doi.org/10.1086/516614 PMID: 17443482
3. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013; 100:446–54. https://doi.org/10.1016/j.antiviral.2013.09.015 PMID: 24084488
4. Sissoko D, Laouenan C, Folkesson E, M’Lebing AB, Beavogui AH, Baize S, et al. Experimental treatment with Favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med 2016; 13:e1001967. https://doi.org/10.1371/journal.pmed.1001967 PMID: 26930627
5. Kumagai Y, Murakawa Y, Hasunuma T, Aso M, Yuji W, Sakurai T, et al. Lack of effect of favipiravir, a novel antiviral agent, on the QT interval in healthy Japanese adults. Int J Clin Pharmacol Ther 2015; 53:666–74. https://doi.org/10.5414/CP202388 PMID: 26308176
6. Al-Khatib SM, LaPointe NM, Kramer JM, Callff RM. What clinicians should know about the QT interval. JAMA 2003; 289:2120–7. https://doi.org/10.1001/jama.289.16.2120 PMID: 12709470
7. Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 2002; 46:977–81. https://doi.org/10.1128/AAC.46.4.977-981.2002 PMID: 11897578

8. Oestreich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res 2014; 105:17–21. https://doi.org/10.1016/j.antiviral.2014.02.014 PMID: 24583123

9. Van Herp M, Declerck H, Decroo T. Favipiravir—a prophylactic treatment for Ebola contacts? Lancet 2015; 385:2350. https://doi.org/10.1016/S0140-6736(15)61095-9 PMID: 26088635

10. Bai CQ, Mu JS, Kargbo D, Song YB, Niu WK, Nie WM, et al. Clinical and virological characteristics of Ebola virus disease patients treated with favipiravir (T-705)—Sierra Leone, 2014. Clin Infect Dis 2016; 63:1288–94. https://doi.org/10.1093/cid/ciw571 PMID: 27553371

11. Rodvold KA, Neuhauser M. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Pharmacotherapy 2001; 21:233S–252S. PMID: 11642690

12. Traebert M, Dumotier B, Meister L, Hoffmann P, Dominguez-Estevez M, Suter W. Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells. Eur J Pharmacol 2004; 484:41–8. PMID: 14729380

13. Hoom EJ, van der Hoek J, de Man RA, Kuipers EJ, Bolwerk C, Zietse R. A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis 2010; 56:112–6. https://doi.org/10.1053/ajkd.2009.11.019 PMID: 20189276

14. Sueblinvong V, Johnson DW, Weinstein GL, Connor MJ Jr, Crozier I, Liddell AM, et al. Critical care for multiple organ failure secondary to Ebola virus disease in the United States. Crit Care Med 2015; 43:2066–75. https://doi.org/10.1097/CCM.0000000000001197 PMID: 26196353

15. Chertow DS, Childs RW, Arai AE, Davey RT Jr. Cardiac MRI findings suggest myocarditis in severe Ebola virus disease. JACC Cardiovasc Imaging 2017; 10:711–3. https://doi.org/10.1016/j.jcmg.2016.06.004 PMID: 27544899

16. Alves DA, Honko AN, Kortepeter MG, Sun M, Johnson JC, Lugo-Roman LA, et al. Necrotizing scleritis, conjunctivitis, and other pathologic findings in the left eye and brain of an Ebola virus-infected Rhesus Macaque (Macaca mulatta) with apparent recovery and a delayed time of death. J Infect Dis 2016; 213:57–60. https://doi.org/10.1093/infdis/jiv357 PMID: 26135408

17. Martines RB, Nq DL, Greer PW, Rollin PE, Zaki SR. Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses. J Pathol 2015; 235:153–74. https://doi.org/10.1002/path.4456 PMID: 25297522

18. Mentre F, Taburet AM, Guedj J, Angliaret X, Keita S, de Lamballerie X, et al. Dose regimen of favipiravir for Ebola virus disease. Lancet Infect Dis 2015; 15:150–1. https://doi.org/10.1016/S1473-3099(14)71047-3 PMID: 25435054